Stone Pharmaceuticals invested 1.452 billion yuan in research and development in the first half of the year, and sales of albumin yew alcohol increased by 70.9%

Among them, the revenue of the pharmaceutical business was RMB10,231 million, up 16.7% YoY, the revenue of vitamin C (API) business was RMB1,005 million, down 13.2% YoY, and the revenue of the antibiotic (API) business was RMB478 million, down 10.0% YoY.
specific products, sales of neurological disease products Erbip (butyl benzene softgels and injections) increased by 29.7% and Orinen (Orasitan capsules and freeze-dried powder needles) decreased by 64.7%. sales of
anti-tumor products queer (injection with yew alcohol albumin binding), Zin youli (polyglycol recombinant human granulocyte stimulant injections) and polymetin (hydrochloric acid dorobi star lipid injections) increased by 70.9%, 53.5% and 23.7%, respectively. sales of
cardiovascular products Xuanning (Malay acid left ammonia chloride tablets and dispersion tablets) also reached 30.6%, while anti-infected products recorded sales revenue of RMB1,371 million, a decrease of 17.3% YoY.
mainly affected by policies such as antibiotic restrictions, the market for anti-infected products is relatively weak.
, coupled with the period of the people to take infection prevention and control measures against the epidemic, the number of infections significantly reduced, the demand for related drugs also decreased accordingly.
respiratory disease products recorded sales revenue of RMB256 million, an increase of 50.4% YoY.
, arbidor hydrochloride tablets are broad-spectrum antiviral drugs, mainly used to treat viral infections represented by influenza.
Because of its good clinical efficacy, as well as excellent performance in the treatment of neo-coronavirus pneumonia, has been written into the national influenza diagnosis and treatment program and "new coronavirus pneumonia diagnosis and treatment program", the first half of the rapid release, to achieve the ideal sales revenue.
the field of diabetes, Ishido Group's main products include Lin Meixin (Gremethylue dispersion tablets) and Synthesium (diphthalphetone hydrochloride tablets).
addition, Acapo sugar tablets were approved in the first half of this year, and Stone Pharmaceuticals said it expected to enter the market quickly through its good coverage of the OTC market, bringing new growth momentum to the therapeutic sector.
first half of 2020, diabetes products recorded sales revenue of RMB173 million, an increase of 32.6% YoY.
Stone Pharmaceuticals currently has 25 drugs in the registration review pending approval phase, 42 products in clinical trials (including 31 innovative drugs and 11 new preparations), 9 products undergoing bioethic trials, and 7 products pending approval for clinical approval (6 domestic and 1 United States).
Group is mainly in the study of products: the original title: 25 drugs in the registration and approval stage! Stone Pharmaceutical Group invested 1.452 billion yuan in research and development in the first half of the year, and sales of albumin yew alcohol increased by 70.9%